Beyond The Printed Page

  1. Tech, Tax Cuts, Trump, & More — A Diversity Of Biopharma Perspectives For 2019
    11/26/2018

    Seven biopharmaceutical industry thought leaders weigh in on technology, tax cuts, and the political landscape to help you get ready for the coming year.

  2. 6 Biopharma Executives On Breakthroughs For 2019
    11/19/2018

    Six biopharmaceutical executives share their thoughts on therapeutic categories where they’d like to see breakthroughs in 2019 and beyond.

  3. What Can Be Done To Save Biopharma’s Broken Image?
    11/14/2018

    Rob Wright shares a personal anecdote about his experience of breaking into the biopharmaceutical industry, along with insight from three biopharma CEOs on what can be done to save the industry’s

  4. Are You Paying It Forward As A Leader?
    10/22/2018

    Liz Barrett, CEO of Novartis Oncology, discusses taking a proactive approach toward mentoring tomorrow’s leaders.

  5. Novartis Oncology CEO Liz Barrett On Balancing Career And Family
    10/16/2018

    Novartis Oncology CEO, Liz Barrett, on career advancement and family, a common challenge for women in the workplace.

  6. Challenges Of Transformation And Balancing An Internal And External Network From BMS’s Lou Schmukler
    9/24/2018

    Lou Schmukler, president of global product development and supply at Bristol-Myers Squibb, provides a preview as to his approach to transformation the company’s product development and manufacturing operations, along with insight into the world of biopharmaceutical outsourcing.

  7. A Primer On Biopharma Manufacturing From Bristol-Myers Squibb’s Lou Schmukler
    9/17/2018

    Lou Schmukler, president of global product development and supply at Bristol-Myers Squibb, explains some of the nuances between small and large molecule drug manufacturing. 

  8. Amgen’s Acquisition Of Onyx Pharmaceuticals — Through The Eyes Of Tony Coles
    8/27/2018

    Tony Coles, M.D., former CEO of Onyx Pharmaceuticals, provides his perspective on Amgen’s $9.7 billion acquisition of Onyx.

  9. Tony Coles On The Importance Of Courage In Leadership
    8/20/2018

    Tony Coles, M.D., chairman and CEO of Yumanity Therapeutics, discusses the decision to acquire Proteolix for $800 million when serving as the CEO of Onyx Pharmaceuticals.

  10. Tony Coles On The Passing Of A Scientific Icon
    8/13/2018

    Tony Coles, M.D., chairman and CEO of Yumanity Therapeutics, talks about the loss of Susan Lindquist, one of the company’s cofounders.